Overview

Pharmacokinetic Profile of Inhaled Liposomal Amphotericin B in Lung Transplant Recipients - Ambisome Study

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the steady state concentrations of inhaled liposomal amphotericin B (Ambisome®) in lung transplant recipients via aerosolized nebulization.
Phase:
Phase 3
Details
Lead Sponsor:
University of Pittsburgh
Collaborator:
Astellas Pharma US, Inc.
Treatments:
Amphotericin B
Liposomal amphotericin B